PURPOSE: To study the characteristics of borderline tumors (BOT) diagnosed during pregnancy, as either first diagnosis or relapse, to evaluate safety of expectant management. METHODS: 15 women affected by BOT during pregnancy were included, to evaluate clinical and histo-pathological characteristics. Age of patient, parity, gestational age, follow-up time, size of tumor, surgical approach, type and timing of surgery, FIGO stage, and histologic type were obtained through retrospective review. RESULTS: All patients except one were diagnosed with serous BOT (BOTs). Median follow-up time was 147 ± 57 months. Eight women received first diagnosis of BOT and seven had diagnosis of BOT recurrence during pregnancy, including three with a second relapse and four with a third relapse. BOT were diagnosed at FIGO stage I in most patients (75%) of the first group and in 14.3% of the second group, respectively. Micropapillary pattern was present in 71.4% of patients with first diagnosis of BOT, but only in 14.2% in case of relapse. All relapses were BOTs. No patient with BOT and concomitant pregnancy developed an invasive recurrence later. Overall, 24 relapses occurred in 10 patients (66.7%). Altogether 24 pregnancies occurred during follow-up, with a high livebirth rate (91.6%) and only 2 spontaneous miscarriages. CONCLUSION: According to our experience, an "expectation management" could be a safe option in case of both relapse of BOTs during pregnancy and first suspicion of BOT in pregnant women at advanced gestational age.
PURPOSE: To study the characteristics of borderline tumors (BOT) diagnosed during pregnancy, as either first diagnosis or relapse, to evaluate safety of expectant management. METHODS: 15 women affected by BOT during pregnancy were included, to evaluate clinical and histo-pathological characteristics. Age of patient, parity, gestational age, follow-up time, size of tumor, surgical approach, type and timing of surgery, FIGO stage, and histologic type were obtained through retrospective review. RESULTS: All patients except one were diagnosed with serous BOT (BOTs). Median follow-up time was 147 ± 57 months. Eight women received first diagnosis of BOT and seven had diagnosis of BOT recurrence during pregnancy, including three with a second relapse and four with a third relapse. BOT were diagnosed at FIGO stage I in most patients (75%) of the first group and in 14.3% of the second group, respectively. Micropapillary pattern was present in 71.4% of patients with first diagnosis of BOT, but only in 14.2% in case of relapse. All relapses were BOTs. No patient with BOT and concomitant pregnancy developed an invasive recurrence later. Overall, 24 relapses occurred in 10 patients (66.7%). Altogether 24 pregnancies occurred during follow-up, with a high livebirth rate (91.6%) and only 2 spontaneous miscarriages. CONCLUSION: According to our experience, an "expectation management" could be a safe option in case of both relapse of BOTs during pregnancy and first suspicion of BOT in pregnant women at advanced gestational age.
Authors: F Mascilini; L Savelli; M C Scifo; C Exacoustos; I E Timor-Tritsch; I De Blasis; M C Moruzzi; T Pasciuto; G Scambia; L Valentin; A C Testa Journal: Ultrasound Obstet Gynecol Date: 2017-07 Impact factor: 7.299
Authors: Mark E Sherman; Jules Berman; Michael J Birrer; Kathleen R Cho; Lora Hedrick Ellenson; Fred Gorstein; Jeffrey D Seidman Journal: Hum Pathol Date: 2004-08 Impact factor: 3.466
Authors: Mark E Sherman; Pamela J Mink; Rochelle Curtis; Timothy R Cote; Sandra Brooks; Patricia Hartge; Susan Devesa Journal: Cancer Date: 2004-03-01 Impact factor: 6.860
Authors: Luigi Della Corte; Antonio Mercorio; Paolo Serafino; Francesco Viciglione; Mario Palumbo; Maria Chiara De Angelis; Maria Borgo; Cira Buonfantino; Marina Tesorone; Giuseppe Bifulco; Pierluigi Giampaolino Journal: Front Surg Date: 2022-08-23